Women are less likely to be eligible for AD trials than men.
Based on commonly used inclusion criteria of clinical trials, women are less likely to be eligible for participation in AD drug trials than men. This discrepancy seems mainly related to lower MMSE at presentation and lack of caregiver presence. These results provide clues for design of trials to be alert for equal inclusion of women.
Authors
- Xiaotian T. Fang (ORCID: https://orcid.org/0000-0001-9706-1122)
- Sietske A.M. Sikkes (ORCID: https://orcid.org/0000-0002-0161-3656)
- Everard G.B. Vijverberg (ORCID: https://orcid.org/0000-0003-3879-884X)
- Siti S. Syaziyah
- Lieza G. Exalto
- Yvonne M.F. Lim
- Wiesje M. van der Flier
- Niels D. Prins
Institutions
- Ministry of Health (MY)
- Netherlands Institute for Neuroscience (NL)
- Fresenius Kabi (Netherlands) (NL)
- Yulius (NL)
- Amsterdam University Medical Centers (NL)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_104840
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00